IPP-204106 / ImmuPharma  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
IPP-204106 / ImmuPharma
IP N02, NCT01711398 / 2012-000939-42: Dose-finding Adaptive Phase I/IIa Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of IPP-204106N on Advanced Solid Tumors

Completed
1/2
15
Europe
Drug
Elro Pharma
All Solid Tumors
09/14
02/15

Download Options